RT Journal Article
SR Electronic
T1 The experiences of 33 national COVID-19 dashboard teams during the first year of the pandemic in the WHO European Region: a qualitative study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.23.21266747
DO 10.1101/2021.11.23.21266747
A1 Barbazza, Erica
A1 Ivanković, Damir
A1 Davtyan, Karapet
A1 Poldrugovac, Mircha
A1 Yelgezekova, Zhamin
A1 Willmington, Claire
A1 Meza-Torres, Bernardo
A1 Bos, Véronique L.L.C.
A1 Fernandes, Óscar Brito
A1 Rotar, Alexandru
A1 Nuti, Sabina
A1 Vainieri, Milena
A1 Carinci, Fabrizio
A1 Azzopardi-Muscat, Natasha
A1 Groene, Oliver
A1 Novillo-Ortiz, David
A1 Klazinga, Niek
A1 Kringos, Dionne
YR 2021
UL http://medrxiv.org/content/early/2021/11/24/2021.11.23.21266747.abstract
AB Background Governments across the WHO European Region prioritized dashboards for reporting COVID-19 data. The ubiquitous use of dashboards for public reporting is novel. This study explores the development of COVID-19 dashboards during the pandemic’s first year and common barriers, enablers and lessons from the experiences of teams responsible for their development.Methods Multiple methods were applied to identify and recruit COVID-19 dashboard teams using a purposive, quota sampling approach. Semi-structured group interviews were conducted between April– June 2021. Using elaborative coding and thematic analysis, descriptive and explanatory themes were derived from interview data. A validation workshop with study participants was held in June 2021.Results Eighty informants, representing 33 national COVID-19 dashboard teams across the WHO European Region participated. Most dashboards were launched swiftly in the first months of the pandemic, between February–May 2020. The urgency, intense workload, limited human resources, data and privacy constraints, and public scrutiny were common to the initial development stage. Themes related to barriers or enablers were identified pertaining to the pre-pandemic context, pandemic itself, people and processes, software, data, and users. Lessons emerged around the themes of simplicity, trust, partnership, software and data, and change.Conclusions COVID-19 dashboards were developed in a learning-by-doing approach. The experiences of teams signal initial under-preparedness was compensated by high-level political endorsement, the professionalism of teams, accelerated data improvements, and immediate support of commercial software solutions. To leverage the full potential of dashboards, investments are needed at team-, national- and pan-European-level.Competing Interest StatementThe authors declare that they have no competing interests. DNO, KD and NAM are staff members of the WHO. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the WHO.Funding StatementThis work was carried out by the Marie Skłodowska-Curie Innovative Training Network (HealthPros - Healthcare Performance Intelligence Professionals) that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement Nr. 765141.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical requirements of the primary research affiliation to Amsterdam University Medical Centers of the University of Amsterdam, the Netherlands, for which an exception applies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary information. The data generated and/or analysed in the study are not publicly available due to participant anonymity.